Intervention studies that prescribed cadence in physical activity programme |
Johnson582006 | 8 type 2 diabetes patients; 40–70 years (54.4±7.5 years) | Single group pre-post; 12 weeks | 30 min/day, 3 days/wk of cadence-based ‘pick up the pace’ (PUP) walking to increase speed/intensity Participants first determined normal cadence during a 10 min walk (accumulated steps/10 min); normal cadence then multiplied by 1.1 (ie, 10% increase) to provide PUP training cadence
| Intervention: Pedometer—device make and model NR Assessment: Accelerometer —AMP 331 (Dynastream, Calgary, AB, Canada | Average walking speed (km/hour) for PUP walking, non-PUP walking on PUP days and non-PUP days: Week 1—5.2±0.7, 3.2±0.5, and 3.1±0.4 Week 4—5.4±0.7, 3.2±0.5, and 3.1±0.3 Week 12—5.7±0.8, 3.0±0.5, and 3.3±0.4
Heart rate response to modified Bruce protocol significantly lower (data presented only in figure) Haemoglobin A1c decreased (−0.35±0.55%), but was not statistically different
|
Richardson592007 | 30 sedentary adults with type 2 diabetes; >18 years (52±12 and 53±9 years for groups, respectively) | Randomised trial; 6 weeks | Lifestyle goals (LG; n=17) targeting individualised daily total step count; Structured goals (SG; n=13) targeting bout steps, defined as walking for ≥10 min at ≥60 steps/min
| Omron HJ-720IT (Omron Healthcare, Lake Forest, Illinois) | LG group significantly increased total steps (2122±3179, P=0.01), whereas SG group failed to reach statistical significance (1697±3564, P=0.11). No between-group difference (P=0.73) Both groups significantly (P<0.05) increased bout steps (1783±2741 vs 2101±2815 for LG and SG, respectively). No between-group difference (P=0.76)
|
Marshall60 2013 | 180 Latina women; 18–65 years (36.94±8.86, 35.27±8.76 and 35.42±8.41 years for groups, respectively) | Randomised trial; 12 weeks | Theory-based PA intervention+one of the following:Self-selected goal (SELF, n=60) A goal of 10 000 steps per day (FREQUENCY, n=60) A goal of 3000 steps in 30 min (CADENCE, n=60)
| Intervention: Yamax Digi-Walker SW-200 (New Lifestyles, Lees Summit, Missouri), Assessment: Accelerometer ActiGraph 7164 (ActiGraph, Pensacola, Florida) | CADENCE group engaged in similar levels of MVPA compared with SELF and FREQUENCY groups CADENCE group more likely to engage in bouts of MVPA>10 min compared with SELF (P=0.01) and FREQUENCY (P=0.001) groups
|
Bouchard61 2013 | 25 inactive older adults; aged >65 years (71.9±4.5) | Randomised trial; 8 weeks | | Intervention: HR monitor—Polar Accurex Plus (Polar Electro, Woodbury, New York, USA) and Pedometer (Yamax Health Sports, San Antonio, Texas, USA) Assessment: the long version of the International Physical Activity Questionnaire; CR-10—perception of aerobic exercise intensity on the Borg scale | Only HR monitor and pedometer groups increased total aerobic exercise time as measured by HR monitor (both P<0.01) No group improved the time spent at MVPA (≥40% of HRR) No group improved the ability to correctly identify moderate intensity, but an observed tendency in pedometer group (P=0.07)
|
Slaght62 2017 * | 42 inactive older adults; aged >65 years (66–77) | Randomised trial; 12 weeks | Individualised walking cadence prescription using pedometer (n=20)—achieving moderate-to-vigorous intensity physical activity in 10 min bouts Control group (n=22)— walking at a moderate-to-vigorous intensity in 10 min bouts at least 150 min/wk without any additional information
| Intervention: Pedometer (StepRx, Ontario, Canada) Assessment: Pedometer (StepRx, Ontario, Canada) and accelerometer (Phillips, Respironics, Oregon, USA) | |
Intervention studies that analysed accelerometer data using cadence-based metrics |
Gardner632011 | 119 peripheral artery disease patients with intermittent claudication; 66±12, 65±11 and 65±10 years for groups, respectively | RCT; 12 weeks | Supervised treadmill-walking programme (n=33)–3 days/week, intermittent walking at ~2 mph for 15 min/session (first 2 weeks) progressing to 40 min (final 2 weeks) Home-based walking programme (n=29)—3 days/week, intermittent walking at self-selected speed for 20 min/session (first 2 weeks) progressing to 45 min (final 2 weeks) ) Control group—usual care (n=30)
| Accelerometer - StepWatch3 (Cyma, Mountlake Terrace, Washington) | Home-based walking programme resulted in significant differences both within (P<0.01) and between groups (P<0.01) (ie, control group) Daily average (2.2±4.0 vs −0.6±3.6 steps/min) Maximum 20 min (6.6±12.2 vs −3.8±13.8) Maximum 30 min (6.8±11.4 vs −3.6±10.6) Maximum 60 min (5.0±9.4 vs −2.6±8.4)
Cadence indicators (change-scores) home-based vs control group (all P<0.01) No significant within-group or between-group changes in cadence indicators for supervised treadmill-walking and control groups
|
Rider64 2014 | 28 adults; 21–65 years (54.7±7.9 years) | Randomised trial; 8 weeks | Diet and PA intervention targeting MVPA time ≥40 min/day, 5 days/wk Diet and PA intervention targeting MVPA time ≥40 min/day, 5 days/wk+reducing TV time ≤10 hours/week NB: no between-group differences at 8 weeks for PA outcomes; group data collapsed for this analysis | Omron HJ-720ITC (Omron Healthcare, Lake Forest, Illinois) | Aerobic steps/day (ie, cadence >60 steps/min in ≥10 min bouts) Increased (baseline: 662±1008 steps/day; 8 weeks: 2514±2105 steps/day; P=0.001) Aerobic min/day increased (baseline: 6.0±14.9 min; 4 weeks: 25.7±27.0 min, P<0.05; and 8 weeks: 22.5±28.3; P>0.05) Aerobic steps/min (cadence) increased (baseline: 60±53.8 steps/min; 4 weeks: 109±23.0 steps/min, P<0.05; and 8 weeks: 100±36.0 steps/min, P>0.05) Participants exceeded 100 steps/min for 89% of their aerobic minutes
|
Mansfield65 2016 | 57 subacute patients with stroke; 64 (range 22–92) and 61.5 (24–81) years for groups, respectively | Randomised controlled trial; median duration of intervention 14 (range 4–91) and 14 (3–36) days for groups, respectively | Intervention (n=29) - daily feedback about walking activity, including: walking time, steps/day, average cadence, longest bout duration, number of ‘long’ walking bouts Control (n=28)—no feedback
| Two tri-axial accelerometers – Model X6-2mini (Gulf Data Concepts, Waveland, Mississippi), worn on each limb | No significant between-group differences in change in walking time, number of steps, longest bout duration or number of long walking bouts for the feedback group compared with the control group (P>0.20). Intervention group significantly increased average cadence (76.3 (95% CI 72.9 to 79.8) to 81.1 (77.9 to 84.4) steps/min) compared with control group (76.0 (72.3 to 79.6) to 77.0 (73.7 to 80.3) steps/min; P=0.013, for between-group comparison)
|
Barreira662016 | 90 overweight and obese white and African-American adults; 35–64 years | Randomised trial; 12 weeks | | Accelerometer— ActiGraph GT3X+ (ActiGraph, Pensacola, Florida) | No significant difference for changes in steps/day between groups DE+PA group accumulated significantly more steps in the 80–99, 100–119 and 120+ cadence bands at postintervention (all P<0.02) DE+PA group increased peak 30 and 60 min cadences and steps accumulated within the 100–119 (463±1092 vs56±546 steps; P=0.01) and 120+ (390±999 vs 34±321 steps; P=0.03) cadence bands compared with DE group
|